Monograph
S01EE05 - Tafluprost |
Not porphyrinogenic |
NP |
Rationale
Administered locally in the eye and systemic exposure is insignificant.
Chemical description
Fluorinated analog of prostaglandin F2-alpha.
Therapeutic characteristics
Tafluprost eye drops reduce elevated intraocular pressure in open angle glaucoma and ocular hypertension.
Hepatic exposure
Mean plasma tafluprost acid concentrations were below the limit of quantification of the bioanalytical assay (10 pg/mL) and hepatic exposure is therefore insignificant (SPC).
Metabolism and pharmacokinetics
Tafluprost is a prodrug and is hydrolyzed to the pharmacologically active metabolite, tafluprost acid. Tafluprost acid is further metabolized by glucuronidation and beta-oxidation. CYP450 enzymes are not involved in the metabolism.
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Saflutan.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024